Publicaciones (175) Publicaciones de María Ángeles Castro Iglesias

2023

  1. Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226

2022

  1. Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain

    Farmacia Hospitalaria, Vol. 46, Núm. 6, pp. 327-334

  2. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

  3. No increased risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection after switching protease inhibitor-based antiretroviral therapy

    HIV Medicine, Vol. 23, Núm. 3, pp. 301-306

  4. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  5. Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV

    AIDS, Vol. 36, Núm. 5, pp. 691-695

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus

    European Journal of Hospital Pharmacy, Vol. 28, Núm. 1, pp. 16-21

  3. Reply to “Critically ill patients infected with HIV: 15 years of experience”

    Medicina Intensiva

  4. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure

    Journal of Viral Hepatitis, Vol. 28, Núm. 9, pp. 1319-1324

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Effectiveness and safety of direct-acting antivirals in hepatitis C infected patients with mental disorders: Results in real clinical practice

    Journal of Medical Virology, Vol. 92, Núm. 12, pp. 3488-3498

  3. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients

    European Journal of Hospital Pharmacy, Vol. 27, Núm. 1 e, pp. E41-E47

  4. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  5. Epidemiology and outcome of HIV-infected patients admitted to the ICU in the current highly active antiretroviral therapy era

    Medicina Intensiva, Vol. 44, Núm. 5, pp. 283-293

  6. Hepatitis E 3ra Genotype Infection in People Living With HIV in Spain

    Frontiers in Microbiology, Vol. 11

  7. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2019

  1. DBP rs16846876 and rs12512631 polymorphisms are associated with progression to AIDS naïve HIV-infected patients: A retrospective study

    Journal of Biomedical Science, Vol. 26, Núm. 1

  2. Despistaje de la infección por el virus de inmunodeficiencia humana en Atención Primaria mediante indicadores de sospecha: estudio DIVAPIS

    Galicia Clínica, Vol. 80, Núm. 4, pp. 70-73

  3. Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain

    Frontiers in Microbiology, Vol. 10, Núm. APR